Total
0
Shares
Levitee Labs - CEO, Pouya Farmand.
CEO, Pouya Farmand.
Source: Levitee Labs.
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Common shares of Levitee Labs are now eligible to be electronically cleared and settled through the DTC
  • Shares of Levitee Labs are now available to a much broader audience of American investors
  • The company’s shares will continue to trade on the CSE under the symbol LVT
  • Levitee Labs is redefining mental healthcare through the use of psychedelic medicines and therapies
  • Levitee Labs Inc. (LVT) is up 2.50 per cent, trading at C$0.41 per share at 11:30 am ET

Common shares of Levitee Labs (LVT) are now eligible to be electronically cleared and settled through the DTC.

Securities that are eligible to be electronically cleared and settled through DTC are considered “DTC eligible”. With an accelerated settlement period and reduced costs for investors and brokers, DTC eligibility is expected to simplify the process of trading and enhance the liquidity of the company’s shares in the United States.

Levitee Labs Inc’s common shares have been made eligible for book-entry delivery and depository services of the Depository Trust Company to facilitate electronic settlement of transfers of its common shares in the United States.

DTC eligibility will simplify the process of trading and is expected to enhance the liquidity of the company’s common shares on the OTC Markets where Levitee Labs trades under the symbol LVTTF.

The company’s shares will continue to trade on the CSE under the symbol LVT.

Founder and CEO Pouya Farmand commented on the announcement.

“We are pleased to have obtained our DTC eligibility. This eligibility will simplify the process of trading shares in the USA, which will be beneficial to Levitee and our shareholders. With DTC eligibility, the increased accessibility and visibility is expected to attract greater investment and trading liquidity from American investors as our shares will be available to a broader range of investors as we continue to expand our business.”

Levitee Labs is redefining mental healthcare through the use of psychedelic medicines and therapies.

Levitee Labs Inc. (LVT) is up 2.50 per cent, trading at C$0.41 per share at 11:30 am ET.

More From The Market Herald

" Andlauer Healthcare Group (TSX:AND) completes $169M bought deal offering

Andlauer Healthcare Group Inc. (AND) and Andlauer Management Group Inc. completed a bought deal offering of 3.5 million subordinate voting shares (SVSs).

" Avricore (TSXV:AVCR) expands HealthTab to select Shoppers Drug Mart locations in BC

Avricore Health (AVCR) has expanded its patient testing with the HealthTab platform in select Shoppers Drug Mart pharmacies in BC.

" Clearmind (CSE:CMND) signs development and supply agreement with Aragen Life Sciences

Clearmind Medicine (CMND) will work with Aragen Life Sciences to produce its innovative molecule, 5-Methoxy-2-aminoindane (MEAI).

" Aptose (TSX:APS) expands senior leadership team

Aptose Biosciences (TSX: APS) has appointed two key members to its management team to support its finance and operations functions.